# CBD Oil for Reducing Emotional Impact of COVID-19

> **NCT04603781** · PHASE2,PHASE3 · SUSPENDED · sponsor: **University of Texas at Austin** · enrollment: 200 (estimated)

## Conditions studied

- Anxiety Depression
- Alcohol Abuse
- Substance Abuse
- Anger
- Sleep Disturbance
- Stress Reaction

## Interventions

- **DIETARY_SUPPLEMENT:** CBD Isolate
- **DIETARY_SUPPLEMENT:** Full Spectrum CBD Oil
- **DIETARY_SUPPLEMENT:** Broad-Spectrum CBD Oil
- **DIETARY_SUPPLEMENT:** Placebo Oil

## Key facts

- **NCT ID:** NCT04603781
- **Lead sponsor:** University of Texas at Austin
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-12-04
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Why stopped:** Suspended (The UT IRB determined that CBD oil is being used as a drug as defined by the FDA. Therefore, an IND must be obtained for the use of CBD oil in this research study in accordance with FDA regulations, 21 CFR 312.)
- **Last updated:** 2023-11-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04603781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04603781, "CBD Oil for Reducing Emotional Impact of COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04603781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*